Home › Funds › StepStone Group LP › PHAT
StepStone Group LP position in PHAT
Phathom Pharmaceuticals, Inc. · Health Care
StepStone Group LP reported holding 422,085 shares of PHAT (Phathom Pharmaceuticals, Inc.) in its Q2 2026 13F filing — a position valued at US$4.6M, representing 0.21% of its reported portfolio and ranking #11 among its reported holdings. StepStone Group LP has disclosed PHAT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How StepStone Group LP's PHAT position evolved
StepStone Group LP first disclosed a stake in PHAT in Q3 2023 at 422,085 shares (US$4.4M). The position peaked in Q3 2024 at 422,085 shares, worth US$7.6M. Across 12 filings, StepStone Group LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 422,085 shares valued at US$4.6M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 422.08K | $4.38M | New |
| Q4 2023 | 422.08K | $3.85M | Hold |
| Q1 2024 | 422.08K | $4.48M | Hold |
| Q2 2024 | 422.08K | $4.35M | Hold |
| Q3 2024 | 422.08K | $7.63M | Hold |
| Q4 2024 | 422.08K | $3.43M | Hold |
| Q1 2025 | 422.08K | $2.65M | Hold |
| Q2 2025 | 422.08K | $4.05M | Hold |
| Q3 2025 | 422.08K | $4.97M | Hold |
| Q4 2025 | 422.08K | $4.97M | Hold |
| Q1 2026 | 422.08K | $4.69M | Hold |
| Q2 2026 | 422.08K | $4.58M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PHAT and 13F data
PHAT (Phathom Pharmaceuticals, Inc.) is a Health Care company. 31 other funds we track also report a position in PHAT — the largest reported positions include Frazier Life Sciences Management, L.P. (US$135.3M), Medicxi Ventures Management (Jersey) Ltd (US$81.0M), Carlyle Group Inc. (US$37.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PHAT
- Frazier Life Sciences Management, L.P. 12.47M sh · $135.26M · Q2 2026
- Medicxi Ventures Management (Jersey) Ltd 7.46M sh · $80.99M · Q2 2026
- Carlyle Group Inc. 3.50M sh · $37.94M · Q2 2026
- NEA Management Company, LLC 1.96M sh · $21.27M · Q2 2026
- 683 Capital Management, LLC 1.85M sh · $20.07M · Q2 2026
- Catalys Pacific, LLC 1.88M sh · $13.74M · Q3 2026
- Propel Bio Management, LLC 1.05M sh · $11.40M · Q2 2026
- EcoR1 Capital, LLC 625.00K sh · $6.78M · Q2 2026
More on StepStone Group LP
FAQ
How long has StepStone Group LP held PHAT?
StepStone Group LP has disclosed PHAT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is StepStone Group LP's current position in PHAT?
As of Q2 2026, StepStone Group LP holds 422.08K shares of PHAT (Phathom Pharmaceuticals, Inc.), valued at $4.58M, representing 0.21% of its reported portfolio and ranking #11.
Has StepStone Group LP been buying or selling PHAT?
In the latest 13F filing (Q2 2026), StepStone Group LP held unchanged its position in PHAT. The position peaked in Q3 2024 at 422.08K shares.
Which other funds hold PHAT?
Other major institutional holders of PHAT include Frazier Life Sciences Management, L.P., Medicxi Ventures Management (Jersey) Ltd, Carlyle Group Inc., among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.